Cardiovascular repair with bone marrow-derived cells.
Cardiovascular repair with bone marrow-derived cells.
复制标题
骨髓衍生细胞的心血管修复。
DOI：
10.5045/br.2013.48.2.76
复制
发表时间：
2013-06
期刊：
影响因子：
2.2
通讯作者：
Yoon YS
中科院分区：
文献类型：
--
作者：
Kim WS;Lee S;Yoon YS
虽然骨髓（BM）来源的细胞因其良好的临床前结果而得到了全面的研究，但临床试验显示出有争议的结果。与之前的认识不同，最近的研究已经证实，体液和旁分泌作用是组织再生和功能恢复的关键机制，而不是脑卒中来源的细胞转分化为心血管组织。对脑转移源性细胞的理解的进展进一步导致探索有效的方法来分离和获得不需要动员的足够数量的细胞群，这些细胞群最终具有更高的治疗潜力。因此，造血CD31+细胞普遍存在于骨髓和外周血中，在最近的研究中已被发现具有血管生成和血管生成活性，并在缺血性组织中显示出强大的治疗新生血管的潜力。本文将讨论脑转移源性细胞治疗的最新进展以及新发现的CD31+细胞的意义。
While bone marrow (BM)-derived cells have been comprehensively studied for their propitious pre-clinical results, clinical trials have shown controversial outcomes. Unlike previously acknowledged, more recent studies have now confirmed that humoral and paracrine effects are the key mechanisms for tissue regeneration and functional recovery, instead of transdifferentiation of BM-derived cells into cardiovascular tissues. The progression of the understanding of BM-derived cells has further led to exploring efficient methods to isolate and obtain, without mobilization, sufficient number of cell populations that would eventually have a higher therapeutic potential. As such, hematopoietic CD31+ cells, prevalent in both bone marrow and peripheral blood, have been discovered, in recent studies, to have angiogenic and vasculogenic activities and to show strong potential for therapeutic neovascularization in ischemic tissues. This article will discuss recent advancement on BM-derived cell therapy and the implication of newly discovered CD31+ cells.